REGENXBIO AFFINITY DUCHENNE: Trial of Investigational RGX-202 Gene Therapy

- Posted in Duchenne Expert Webinars, General, Research

In this webinar, Dr. Naz Dastgir, Executive Medical Director and Clinical Development Lead for RGX-202 at REGENXBIO, shared information on the active and enrolling AFFINITY DUCHENNE trial and how families can obtain additional information about RGX-202 and potential clinical trial participation.

Watch HERE

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate